Molly Brewer


Molly Brewer

Research Professor
Office: Carole and Ray Neag Comprehensive Cancer Center
Phone: (860) 679-2100
Email: mbrewer@uchc.edu

 

 

 

Education

  • Bachelor of Science Texas A & M University, Biochemistry, Microbiology, Biological Sciences College Station,Texas 1976 Major: Biology Tufts University Medford, Massachusetts 1971
  • Master of Science in “Statistical Analysis and Clinical Research Design”, University of Michigan School of Public Health 1999
  • Doctor of Medicine State University of New York @ Syracuse College of Medicine Syracuse, New York 1991
  • Doctor of Veterinary Medicine Texas A & M University College of Veterinary Medicine College Station, Texas 1991

POSTGRADUATE TRAINING

  • Galloway Fellow Memorial Sloan-Kettering Cancer Center New York, New York, 1993
  • Resident Obstetrics and Gynecology, Oregon Health Sciences, Portland, Oregon Chairman, Paul Kirk, M. D. 1995
  • Fellow Department of Gynecologic Oncology UT MD Anderson Cancer Center, Houston, Texas Chairman J. Taylor Wharton, M.D. 1997

Current Research Grants

NIH RO1 CA098341-01A1 Biomedical Engineering Research Grant NIC 8/1/03 – 7/30/07 (Co-Investigator)
“Optical Spectroscopy of Ovarian Cancer”

RO1 National Cancer Institute 9/1/2003-8/31/2008 (Co-Investigator)
“Diagnosis of Ovarian Cancer by Confocal Microendoscopy”

RO1 National Cancer Institute CA119200-01A1 10/1/05 – 9/30/10 (Consultant)
“Optical Imaging of Ovarian Carcinogenesis in a Rat Menopause Model”

UTMDACC Cattlemen for Cancer Research 2004 – 2007 (PI) “Technology Development for Ovarian Cancer Screening”

Awards and Honors

  • Dean’s List, Texas A & M University
  • Honor Society for the Biological Sciences, Texas A & M University 
  • Alpha Omega Alpha Honor Society
  • Robert E.L. Nesbitt, Jr., M. D. Student Award for Exceptional OB/GYN Student 
  • Hal Lee, M. D. Scholarship Award
  • Galloway Fellow, Memorial Sloan-Kettering Cancer Center
  • Member Taskforce on the Treatment of Intraepithelial Neoplasia, AACR, U.S. 
  • Food and Drug Administration.
  • Dean’s Physician-Scientist Career Development Award/Nielsen Award

Journal Publications (1997-2007)

  • Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, and Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 17: 2670-5, 1999.
  • Brewer MA, Mitchell MF, and Bast R. Prevention of ovarian cancer. In Vivo 13: 99-106, 1999.
  • Utzinger U, Brewer M, Silva E, Gershenson D, Bast RC, Mitchell M, and Richards- Kortum R. Reflectance spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 28: 56- 66, 2001.
  • Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC, Follen M, and Richards-Kortum R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med 29: 128-35, 2001.
  • Brewer M, Utzinger U, Satterfield W, Gershenson D, Bast R, Richards-Kortum R, and Follen M. Biomarker modulation in a nonhuman Rhesus primate model for ovarian cancer chemo- prevention. Cancer Epidemiol Biomarkers Prev 10: 889-93, 2001. 
  • Ramirez PT, Ramondetta LM, Burke TW, Gershenson DM, and Brewer MA. Metastatic uterine papillary serous carcinoma to the pericardium. [Case Report] Gynecol Oncol 83: 135-7, 2001.
  • Brewer M, Baze W, Hill L, Utzinger U, Wharton JT, Follen M, Khan-Dagwood-F, and Satterfield W. Rhesus macaque model for ovarian cancer chemoprevention. Comparative Med 51: 424-9, 2001.
  • Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, and Bast R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman Rhesus primate model for ovarian cancer chemo preventive agents. J Biomed Optics 7: 20-6, 2002 
  • Brewer M, Johnson K, Follen M, Gershenson D, and Bast R. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 9: 20-30, 2003. 
  • Zou CP, Vlastos A-T, Yang L, Wang J, Brewer M, and Follen M. Effect of 4-hydroxyphenyl retinamide on human cervical epithelial and cancer cell lines. J Soc Gynecol Invest 10: 41-8, 2003.
  • Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast Jr RC, and Brewer MA*. Specific Keynote: Chemoprevention of ovarian cancer: The journey begins. Gynecol Oncol 88: S59-66, 2003.
  • Berchuck A, Brewer M, Rodriguez G, and Campbell I. Discussion: Ovarian cancer prevention. Gynecol Oncol 88: S67-70, 2003.
  • Drezek RA, Richards-Kortum R, Brewer MA, Feld MS, Pitris C, Ferenczy A, Faupel ML, and Follen M. Optical imaging of the cervix. Cancer 98: 2015-27, 2003.
  • Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, and Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33:1219-24, 2004.
  • Garcia FA, Ranger-Moore J, Barker B, Davis J, Brewer M, Lozevski J, Vinyak S, Liu Y, Yemane J, Hatch K, Alberts DS, Bartels HG, and Bartels PH. Karyometric image analysis for intraepithelial and invasive cervical lesions. Anal Quant Cytol Histol 26: 141-50, 2004.
  • Brewer M, Ranger-Moore J, Greene M, Alberts D, Liu Y, Bartels H, Baruch A, and Bartels P. Preneoplastic changes in ovarian tissue. Anal Quant Cytol Histol 26: 207-16, 2004. Marret H, Sauget S, Giraudeau B, Brewer M, Ranger-Moore J, Body G, and Tranquart F. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med 23: 1629-1939, 2004.
  • Brewer MA, Utzinger U, Barton JK, Hoying JB, Kirkpatrick ND, Brands WR, Davis JR, Hunt K, Stevens SJ, and Gmitro AF. Imaging of the ovary. Technology for Cancer Res Treatment 316:617-27, 2004.
  • Brewer M, Ranger-Moore J, Baruch A, Alberts D, Greene M, Thompson D, Liu Y, Davis J, and Bartels P. Exploratory study of ovarian intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 14: 299-305, 2005.
  • Kirkpatrick ND, Zou C, Brewer MA, Brands WR, Drezek RA, and Utzinger U. Endogenous fluorescence spectroscopy of cell suspensions for chemo preventive drug monitoring. Photochem Photobiol 81: 125-34, 2005.
  • Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, and Zou CP. In vitro model of normal immortalized ovarian surface epithelial cells and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol 98:182-92, 2005.
  • Marret H, Brewer M, Giraudeau B, Tranquart F, Voelker K, and Satterfield W. Ovine model to evaluate ovarian vascularization using contrast enhanced sonography. Comparative Med 55: 150-5, 2005.
  • Srivastava S, Rodriguez J, Rouse A, Brewer M, and Gmitro A. Analysis of confocal micro-endoscope images for automatic detection of ovarian cancer. 2005 IEEE Intl. Conf. on Image Processing (presented at Genoa, Italy, Sept. 11-14, 2005). Image Processing 1: 1113-6, 2005.
  • Zou D, Brewer M, Garcia F, Fuegang J, Wang J, Zang R, and Zou CP. Cactus pear–a natural product in cancer chemoprevention. J Nutr 4:25, 2005. [Article is available from http:/www.nutritionj.com/ content/4/1/25].
  • Ranger-Moore J, Alberts DS, Montironi R, Garcia F, Davis J, Frank D, Brewer M, Mariuzzi GM, Bartels HG, and Bartels HP. Karometry in the early detection and chemoprevention of intraepithelial lesions. Eur J Cancer 41: 1875-88, 2005.
  • Ray JA, Loescher LJ, and Brewer M. Risk-reduction surgery decisions in high risk women seen for genetic counseling. J Genetic Counseling 14(6): 473-84, 2005. [published online December 29, 2005]
  • Marret H, Brewer M, Giraudeau B, Tranquart F, and Satterfield W. Assessment of cyclic changes of microvessels in ovine ovaries using Sonovue contrast-enhanced ultrasound. Ultrasound in Med Biol 32: 163-9, 2006.
  • Brewer M, Kirkpatrick ND, Wharton T, Wang J, Hatch H, Auersperg N, Utzinger U, Gershenson D, Bast R, and Zou C. 4-HPR modulates gene expression in ovarian cells. Intl J Cancer 119(5): 1005-13, 2006.
  • Kanter EM, Walker RM, Marion SL, Brewer M, Hoyer PB, and Barton JK. Dual modality imaging of a novel rat model of ovarian carcinogenesis. J Biomed Optics 11(4): #041123, 2006. Gordon MS. Matei D. Aghajanian C. Matulonis UA. Brewer M. Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, and Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24 (26): 4324-32, 2006.
  • Nammalvar V, Utzinger U, Hsu K, Van den Berg Frans WJ, Bender J, Satterfield W, Brewer M, and Drezek R. Characterization of chemo preventive drug activity in a non-human cynomolgus (Macaca fascicularis) primate model using fluorescence spectroscopy and chemometric analysis. J Biomed Optics in press.
  • Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer Front Biosci. 2007 Jan 1;12:2260-8.